Effects of Sodium-Glucose Cotransporter 2 Inhibitors on Cause-Specific Cardiovascular Death in Patients with CKD: A Meta-Analysis of CKD Progression Trials.
Journal
Clinical journal of the American Society of Nephrology : CJASN
ISSN: 1555-905X
Titre abrégé: Clin J Am Soc Nephrol
Pays: United States
ID NLM: 101271570
Informations de publication
Date de publication:
16 Apr 2024
16 Apr 2024
Historique:
pubmed:
16
4
2024
medline:
16
4
2024
entrez:
16
4
2024
Statut:
aheadofprint
Résumé
Clinical Trial registry name and registration number: ClinicalTrials.gov Identifiers: NCT02065791 (CREDENCE), NCT03036150 (DAPA-CKD), NCT03594110 (EMPA-KIDNEY).
Identifiants
pubmed: 38622766
doi: 10.2215/CJN.0000000000000470
pii: 01277230-990000000-00370
doi:
Banques de données
ClinicalTrials.gov
['NCT03036150', 'NCT03594110', 'NCT02065791']
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
Copyright © 2024 by the American Society of Nephrology.
Références
Nuffield Department of Population Health Renal Studies Group, SGLT2 inhibitor Meta-Analysis Cardio-Renal Trialists' Consortium. Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials. Lancet. 2022;400(10365):1788–1801. doi: 10.1016/S0140-6736(22)02074-8
doi: 10.1016/S0140-6736(22)02074-8
Perkovic V, Jardine MJ, Neal B, et al.; CREDENCE Trial Investigators. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New Engl J Med. 2019;380(24):2295–2306. doi: 10.1056/NEJMoa1811744
doi: 10.1056/NEJMoa1811744
Heerspink HJ, Stefánsson BV, Correa-Rotter R, et al.; DAPA-CKD Trial Committees and Investigators. Dapagliflozin in patients with chronic kidney disease. New Engl J Med. 2020;383(15):1436–1446. doi: 10.1056/NEJMoa2024816
doi: 10.1056/NEJMoa2024816
Herrington WG, Staplin N, Wanner C, et al.; The EMPA-KIDNEY Collaborative Group. Empagliflozin in patients with chronic kidney disease. New Engl J Med. 2023;388(2):117–127. doi: 10.1056/NEJMoa2204233
doi: 10.1056/NEJMoa2204233
Heerspink HJL, Sjöström CD, Jongs N, et al.; DAPA-CKD Trial Committees and Investigators. Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial. Eur Heart J. 2021;42(13):1216–1227. doi: 10.1093/eurheartj/ehab094
doi: 10.1093/eurheartj/ehab094
Jankowski J, Floege J, Fliser D, Böhm M, Marx N. Cardiovascular disease in chronic kidney disease: pathophysiological insights and therapeutic options. Circulation. 2021;143(11):1157–1172. doi: 10.1161/CIRCULATIONAHA.120.050686
doi: 10.1161/CIRCULATIONAHA.120.050686